Phase 3 Trial Comparing IRE and SBRT for Intermediate-Risk Prostate Cancer

NIH registered a Phase 3 clinical trial (NCT07548164) comparing two boost approaches for intermediate-risk prostate cancer patients receiving standard stereotactic body radiotherapy (SBRT): the investigational NanoKnife System using irreversible electroporation (IRE) versus continued standard SBRT boost. The trial is categorized as Phase 3 and appears in the ClinicalTrials.gov registry. This registration documents a new clinical study and does not itself impose compliance obligations on sponsors, investigators, or institutions.

Effects of Accelerated rTMS on Cognitive Function

A single-center, open-label, prospective pilot study registered as NCT07547319 on ClinicalTrials.gov, evaluating the efficacy and tolerability of accelerated repetitive transcranial magnetic stimulation (rTMS) delivered via the EXOMIND™ device (BTL-699-2) for improving cognitive function. The study will enroll 80 adults aged 50-90 years with mild to moderate cognitive impairment (MoCA score 10-25), administering 6 sessions of high-frequency rTMS (6,300 pulses per session at alternating 12, 15, and 18 Hz frequencies) targeting the left dorsolateral prefrontal cortex over approximately 3 weeks. The primary outcome is change from baseline in MoCA score at 1-month follow-up, with a 3-month extended follow-up period to assess sustained cognitive improvements.

CT1182 Injection, Phase 1, Relapsed Non Hodgkin Lymphoma

The NIH has registered a new early Phase 1 clinical trial (NCT07548697) on ClinicalTrials.gov to evaluate the safety, efficacy, metabolic kinetics, and pharmacodynamics of CT1182 injection in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The single-arm, open-label study targets r/r B-NHL subtypes including DLBCL and Follicular Lymphoma. This is a prospective patient enrollment record; no compliance obligations or regulatory actions are imposed.

Phase 2 AML Trial, Sonrotoclax + Azacitidine, Apr 2026

A Phase II open-label clinical trial (NCT07548710) evaluating sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents for adult participants with newly diagnosed acute myeloid leukemia (AML). Participants are stratified by genetic background (FLT3/IDH1 mutation status) and fitness for intensive chemotherapy. The trial involves dose escalation of sonrotoclax from 20 mg/day to 320 mg/day, combined with azacitidine 75 mg/m²/day intravenously on Days 1–7 of each 28-day cycle, with additional agents including gilteritinib for FLT3 mutations or ivosidenib for IDH1 mutations. Enrolled participants will be followed for efficacy and safety outcomes.

Phase 2 Dexamethasone Enema for Radiation-Induced Rectal Injury in Rectal Cancer

A Phase 2 randomized controlled trial (NCT07548736) has been registered on ClinicalTrials.gov evaluating dexamethasone enema for acute radiation-induced rectal injury in 40 rectal cancer patients undergoing pelvic radiotherapy, running from February 2026 to February 2028. The trial hypothesizes that early dexamethasone intervention (starting day 10 of radiotherapy) can reduce injury incidence from an expected 86% to 40%. This registration serves as a public record of an ongoing clinical investigation; it does not create compliance obligations but provides visibility into active research in this therapeutic area.

Streamlining Prescription Fulfillment for REMS and Controlled Substances

USPTO published patent application US20260112471A1, filed October 17, 2025, for a prescription fulfillment system that electronically handles documentation for regulated products subject to REMS (Risk Evaluation and Mitigation Strategy) and controlled substance scheduling requirements. The system connects healthcare provider offices with pharmacies via a platform that automatically populates required forms, eliminating paper and redundant documentation while reducing administrative burden. This application names Robert Chuba, Danielle Suzanne Burroughs, Meggan Curta Sullivan, and Joseph V. Fenton as inventors, with CPC classifications in G16H 20/10, G06F 40/174, and G16H 10/60.

Central Patient Access System for Distributed Electronic Health Record Network

USPTO published patent application US20260111598A1 on April 23, 2026, disclosing a system and method for central patient access to a distributed electronic health record (EHR) network. The system comprises multiple EHR systems connected via secure communication links and a central network node that authenticates patient identities and establishes pre-authorized central patient accounts capable of accessing and modifying patient data across all connected EHR systems. The application (No. 19363561) was filed on October 20, 2025, with six named inventors.

Dual Transcription Generates Health Records From Voice

Acuity Holding Corp. has filed US Patent Application US20260112467A1, published April 23, 2026, covering a dual-transcription AI system that automatically generates health records from vocalized expressions. The system uses two independent transcription models to produce separate transcripts, which are reconciled via a large language model before machine learning determines record data. Desktop automation then populates a record-keeping application based on the extracted data, filed September 19, 2025.

US20260112463A1 Clinical Data Unified Platform System

USPTO published patent application US20260112463A1 for a unified clinical trial data management system invented by Avik Kumar Pal and Yerramalli Subramaniam. The system comprises a centralized database storing clinical trial data and interconnected modules with automated data linking mechanisms that maintain associations between data entries across modules based on predefined rules. The system enforces data dependencies between modules to ensure integrity, automatically creates placeholders in linked modules upon data entry, prevents certain actions until prerequisites are met, and enables real-time data reconciliation without manual intervention or separate application transfers.

AI Avatar Interface for Medical Queries Using Regulatory-Approved Content

The USPTO published patent application US20260111682A1, filed July 30, 2025 (Application No. 19284743), disclosing a method and system for an AI avatar interface that responds to medical queries using regulatory-approved curated content. The system configures a content delivery platform to receive approved content from a content creator and regulatory body, couples the platform to an LLM operating on vector embeddings of tokenized linguistic units, and generates an AI avatar for user interaction. When a user question cannot be answered, the system marks it as unanswerable in a database and sends an indication to both the content creator and the regulatory body.

Cardiac Monitoring Device Management Patent Application US20260112481A1

USPTO published patent application US20260112481A1, filed June 28, 2022 (Application No. 19142797), titled 'Systems and Methods for Managing a Cardiac Monitoring Device with a Monitoring Interval Tracker,' naming inventors Richard Todd Butka, Christopher S. Irving, and Patrick Beaulieu. The invention covers a monitoring interval tracker that generates monitoring intervals for multiple patient care modalities including in-office care, remote monitoring, and heart failure care, and that determines whether to extend monitoring intervals, generate dates of service, or create new monitoring intervals based on transmission data and docket report approvals.

Health Assessment Via Music Media, CHIME AI

The USPTO published patent application US20260112480A1 (A1 kind, filed September 10, 2023, application No. 19117046) for CHIME HEALTH AI INC., with inventors David M. GREENBERG and Igor RADOVANOVIC. The application discloses a processor-executed method for assessing user health by obtaining input data, extracting characteristics, determining health scores based on variation from predetermined values, comparing against health condition thresholds, and generating personalized health messages plus health scores for output devices. CPC classification: G16H 40/63 (Health Informatics).

Generative AI Method for Patient-Specific Electrical Stimulation Prescriptions

USPTO published patent application US20260112472A1 titled 'Method and System for Generating Electrical Stimulation Prescription' filed October 20, 2025, naming Fang-Cheng Liu, Chuan-Feng Lin, and Tung-Shu Yang as inventors. The application discloses a generative AI module that creates exclusive patient-specific electrical stimulation prescriptions by analyzing patient feedback and a database of reference prescriptions, with doctor confirmation before treatment delivery. CPC classifications are G16H 20/30 and G16H 40/63 under health informatics.

Systems and Methods for Identifying Predictive Parameters Based on Clinical Studies

USPTO published patent application US20260112462A1 on April 23, 2026, filed February 6, 2023 under application number 18164877. The invention by inventors Andrew Busey, Amicia Devin Elliott, and Claire Aldridge discloses a system and method for identifying predictive parameters based on clinical study results using AI/machine learning to analyze biological and historical parameters across subject subsets. CPC classifications G16H 10/20 (health informatics) and G06N 20/00 (machine learning) indicate healthcare and AI applications.

Medical Equipment Location and Identification System

USPTO published patent application US20260112478A1, filed October 20, 2025, for systems and methods of identifying and locating medical equipment and supplies. The invention involves transforming clinical names of medical equipment and supplies into inventory names, transmitting those names to an inventory database, and identifying at least one location of the medical equipment or supplies. The publication is an administrative notice of a pending patent application with no immediate compliance obligations for healthcare providers or medical device manufacturers.

KARL STORZ Hospital Report System Using Sensors

KARL STORZ SE & Co. KG filed US Patent Application US20260112468A1 on October 18, 2024 (Application No. 18920489) for a system and method of generating hospital reports using sensor data. The system captures procedure data from at least two sensors, detects and timestamps multiple events during the procedure, synchronizes the events based on their respective timestamps, and generates a machine-readable report containing the merged events. The patent application was published on April 23, 2026.

NEC Rehabilitation Planning System Using Machine Learning

NEC Corporation has filed USPTO patent application US20260112473A1 for a machine learning-based rehabilitation planning system. The system includes a rehabilitation pattern selection unit, an ability value prediction unit that predicts physical ability values after rehabilitation, a repetition control unit, and a determination unit that identifies optimal rehabilitation patterns. The invention aims to efficiently create personalized rehabilitation plans by iteratively selecting rehabilitation patterns and evaluating predicted ability outcomes against predetermined conditions.

Connection Retention Assembly Patent Application by Raymond Feith

USPTO published patent application US20260108717A1, filed by Raymond P. Feith on October 18, 2024, covering a connection retention assembly for medical device connectors. The assembly uses a clamp component with a clip member engaging a mating groove to secure first and second connectors together while allowing removal upon application of separating force. The application includes CPC classifications in the A61M medical device category.

Collagen Stimulation Device with RFID Pen Cartridge

Thomas M. Hitchcock filed patent application US20260108715A1 for a collagen stimulation assembly combining a motorised pen with a single-use cartridge incorporating RFID tag technology. The RFID tag interacts with a transmitter in the pen to detect cartridge status and enable or prevent motor operation accordingly. The application was filed on 2025-10-21 and published on 2026-04-23.

Balloon Catheter Patent by RADEXEL INC, Apr 23

RADEXEL INC filed US Patent Application US20260108710A1 for a balloon catheter design on October 6, 2025. The invention includes an external catheter, an inflatable and deflatable balloon configured to be inserted into or expelled from a target site of a living body, and an internal catheter that moves along the external catheter in two directions for insertion or expulsion. The application was published April 23, 2026.

Medical Tube Securement Device

Alexander Johnson and Phillip Whiting filed US Patent Application US20260108718A1 on June 18, 2025, claiming a medical tube securement device comprising a base member with tab portions and an opening for receiving a tube, plus a clamp member to secure the tube and prevent movement at the tube insertion site. The application, assigned number 19242743, was published on April 23, 2026, with CPC classifications A61M 39/1011, A61M 16/0493, A61M 16/0497, and A61M 2039/1077. This publication makes the invention publicly available for review, opposition, or licensing consideration by competitors and potential investors in the medical device space.

Needleless Connector Patent Application US20260108719A1

USPTO published patent application US20260108719A1 on April 23, 2026, filed October 14, 2025, for a needleless connector design. The application names Soon Yong Park, Christopher Jesse Zolllinger, Jason Andrew Wine, and Kuochu Colin Huang as inventors and describes a flexible valve element with fluid flow pathway features to resist obstruction between the valve head and diaphragm. The invention further includes a diaphragm formed as a bellows to reduce strain during connector activation.

Plastic Stent, UIF, Yonsei University, Apr 23

UIF (University Industry Foundation), Yonsei University filed US Patent Application US20260108711A1 on December 17, 2025 (Application No. 19423245), published April 23, 2026. The invention is a plastic stent comprising a tube-shaped front end portion with an inlet, a central portion extending integrally from the front end, and a rear end portion with an outlet communicating with the inlet via a flow path, wherein the front and rear end portions provide different restoring angles or restoring forces relative to the central portion. Inventors are Jae Hee CHO, Sung Ill JANG, Jung Hyun JO, See Young LEE, and Chan Min JUNG.

Roller Pump Calibration Method and Perfusion System, LivaNova

LivaNova Deutschland GmbH has filed USPTO patent application US20260108720A1 for a roller pump calibration method and extracorporeal perfusion system with an automatic calibration mode. The application, filed on October 22, 2024, was published on April 23, 2026, with inventors Friedemann Schubert and Philipp Löffler listed.

AORTYX S.L. Steerable Catheter Patent Application US20260108705A1

USPTO published patent application US20260108705A1 for AORTYX S.L. covering steerable catheters with dual steering sections configured to steer in opposite directions within the same plane. The application, originally filed on August 22, 2025 (Application No. 19307624), was published on April 23, 2026 and also discloses a system comprising the catheter with a deployable patch deployment device. CPC classifications include A61M 25/0147, A61F 2/2481, and A61F 2002/2484.

Intraluminal Balloon Dilator Patent Filed by Francis, Grace

Application US20260108706A1 for an intraluminal balloon dilator apparatus was filed September 22, 2023 and published April 23, 2026 by inventors Nathan C. Francis and Kenneth Peter Grace. The invention comprises a flexible elongate member positionable within a body lumen and a balloon that transitions from an unexpanded state to an expanded state with a second diameter larger than the first diameter, with a leading edge extending at an angle to engage anatomical walls as the dilator moves through an opening. This published application does not create immediate compliance obligations but may be relevant for companies developing similar medical devices in the balloon dilator space.

Balloon Catheter, KANEKA Corporation, Apr 23

KANEKA CORPORATION has filed a patent application (US20260108708A1) for a balloon catheter designed with dual independent inflation tubes to reduce kinking when navigating curved blood vessel passages. The application, filed on December 18, 2025, lists inventors Kazuki Matsufuji, Masahiro Kojima, and Takahisa Hamabuchi. The invention features a shaft with two sections: a distal first section where inflation tubes are fixed together, and a proximal second section where they are not fixed, allowing flexibility in bent vessel anatomy.

Sheath Assembly For Insertion Of A Catheter Into A Patient

ECP Entwicklungsgesellschaft mbH filed US patent application US20260108707A1 on April 23, 2026, covering a sheath assembly for inserting a cord-shaped element, particularly a catheter, into a patient body. The application describes an introducer sheath and an auxiliary sheath configured to detachably couple and fasten the cord-shaped element. Filing date is September 22, 2025, with Application No. 19335554.

Medical Catheters, Agent Delivery, Expandable Balloon, Deformable Lumens

USPTO published patent application US20260108709A1 filed September 16, 2025 by inventors Thomas ROEWER and Michael P. ALLEN, covering medical delivery devices such as catheters adapted for agent delivery with one or more deformable lumens in collapsed and open configurations, and expandable balloon devices for patient treatment. The application is assigned number 19330503 and claims priority under CPC classifications A61M 25/1018, A61M 25/0023, A61M 25/09, and A61M 2025/0042.

Smart Contract Trusted Execution Data Processing

USPTO published patent application US20260111605A1 filed by inventor Hyeong-Joon Kim on September 29, 2025 (Application No. 19344497), covering a method for processing personal information using a smart contract-based trusted execution environment on a blockchain. The system generates a TEE containing data processing code in response to a request via a smart contract, decrypts data from a generation device, processes it, and returns the result to the requesting device.

Method for Controlled Release of Decryption Key Based on Predefined Trigger Events

The USPTO published patent application US20260111569A1 by inventor Rodney Edward Ast, covering a method and system for encrypting and transferring digital data to trusted trustees using a third-party server, with decryption controlled by predefined trigger events set by the data owner. The system manages trustee role assignments, decentralized encrypted storage, unanimous trigger-event validation by trustees, and decryption capability after event confirmation. The application was filed on 2024-10-19 under Application No. 18920860.

Quantum-Resistant Dataset Comparison Using Mixing and Hashing

USPTO published patent application US20260111610A1 on April 23, 2026, filed by inventor Bruno Sangle-Ferriere (application no. 18927656, filed October 25, 2024). The application describes a cryptographic method for comparing datasets using mixing and hashing techniques that is resistant to attacks by quantum computers. The method enables verification of whether two datasets are identical without requiring both datasets to be present simultaneously in the same apparatus.

AT&T AI Network Configuration Risk Analysis System

AT&T Intellectual Property I, L.P. filed patent application US20260111560A1 on October 21, 2024, published April 23, 2026, covering an AI system for network configuration risk analysis. The system obtains network provisioning configuration information, applies it to an AI model trained on historical configuration data, identifies potential adverse effects from implementing the configuration, and outputs associated risk levels. Five inventors are named: Ajay Singh, Christopher Rollwage, Yuriy Malakov, Ayush Kumar, and Michael Kaiser.

FBXO7 Inhibitor Compounds for Neurodegenerative Disease Treatment - University of Pittsburgh

The University of Pittsburgh has filed patent application US20260109687A1 covering methods for treating neurodegenerative diseases and inflammatory disorders using FBXO7 inhibitor compounds. The application, filed on July 28, 2025, names Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, and Yuan Liu as inventors. The claimed compounds are chemical inhibitors of the E3 ligase subunit FBXO7 that confer neuroprotection and anti-inflammatory activity by stabilizing mitochondria.

Peroxiredoxin 3 Inhibitors and Methods of Use for Treating Cancer

USPTO published patent application US20260109695A1 disclosing peroxiredoxin 3 (PRX3) inhibitor compounds of Formula (I) and methods of use for treating cancer. The application, filed August 25, 2023, names three inventors: W. Todd Lowther, Terrence L. Smalley Jr., and Kimberly J. Nelson. The CPC classifications span C07D (heterocyclic compounds) with therapeutic applications in cancer treatment (A61P 35/00).

Small Molecule Protein Synthesis Modulators

The USPTO published patent application US20260109696A1 assigned to Interdict Bio, Inc., filed September 19, 2025 (Application No. 19333657), covering small molecule compounds and pharmaceutical compositions useful for modulating protein synthesis. The disclosed compounds and methods are directed to treating diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, and KRAS-G12D targets.

Heterocyclic Compounds for Immune Response, Cancer Treatment

The USPTO has published patent application US20260109694A1, filed September 23, 2025 (Application No. 19337361), by inventors Liansheng Li and Pingda Ren. The application covers heterocyclic compounds and pharmaceutical compositions designed to potentiate immune response and treat cancer and other diseases. The compounds are classified under multiple CPC codes including C07D 417/10 and A61K 31/4439. This publication represents the initial public disclosure of the patent application following USPTO examination. Patent applications are informational documents that do not grant enforceable rights until a patent issues after substantive examination. Pharmaceutical and biotechnology entities developing immunotherapies or cancer treatments should monitor this application for potential IP overlap with their own compounds or therapeutic approaches.

KCNT1 Inhibitors and Methods of Use

The USPTO published patent application US20260109692A1 covering KCNT1 inhibitors for treating neurological diseases and conditions related to excessive neuronal excitability or gain-of-function mutations in the KCNT1 gene. The application, filed on 2025-10-17 under Application No. 19361128, names James Thomas Reuberson, Sarah Jane Frith, and Vijayendar Reddy Yedulla as inventors. CPC classifications indicate the compounds fall within heterocyclic organic chemistry (C07D) with pharmaceutical applications (A61K).

Novel Antibiotic Nidaromycin from New Gene Cluster

The USPTO published patent application US20260109688A1 on April 23, 2026, covering a novel antibiotic compound termed nidaromycin and its associated biosynthetic gene cluster (BGC). The application also discloses related genes, nucleic acid molecules, constructs, vectors, and host cells for producing nidaromycin, as well as methods of use. As a patent application, no enforceable rights exist yet; the invention remains subject to examination before any patent grant.

Pyrimidine Derivatives Inhibit c-Kit Kinase for Cancer Treatment

Merck Patent GmbH has filed US Patent Application US20260109697A1, published April 23, 2026, covering 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives as inhibitors of c-Kit kinase for cancer treatment. The application, filed October 30, 2025 (Application No. 19373991), names inventors Dieter Dorsch, Andreas Blum, and Hans-Peter Buchstaller. CPC classifications span C07D 471/04, A61K 31/506, and related pharmaceutical compound categories.

Butenolide-Thiazolidinone Compounds as Agricultural Fungicide

The USPTO published patent application US20260109693A1 for butenolide compounds containing a thiazolidinone structure, filed on October 27, 2023 (Application No. 19114226). The five named inventors — Mingan Wang, Xili Liu, Yihao Li, Tingting Zhang, and Qian Zhang — disclosed compounds with general formula (I) characterised by a butenolide-thiazolidinone structure. The published application claims the compounds demonstrate fungicidal activity against agricultural pathogens and may protect crops, horticulture, and livestock from pathogen invasion.

Nitrogen-Containing Heterocyclic Compounds for Muscarinic Receptor Treatment

USPTO published patent application US20260109700A1 on April 23, 2026, filed October 27, 2023 as Application No. 19121822, disclosing nitrogen-containing heterocyclic compounds represented by formula I and their pharmaceutical salts. The inventors—Deheng Chen, Haifei Jia, Huaqiong Shen, and Lele Zhao—claim the compounds function as positive allosteric modulators of muscarinic receptors for treatment of M receptor-mediated diseases.

Azole Derivatives as SHP2 Inhibitors for Disease Treatment

IRBM S.P.A. has published patent application US20260109699A1 for azole derivatives capable of inhibiting SHP2 phosphatase activity, filed on September 29, 2023 under application number 19114167. The invention covers new chemical compounds and pharmaceutical compositions for treating disorders associated with SHP2 deregulation, with inventors including Alessia Petrocchi, Christian Montalbetti, Romano Di Fabio, Alina Ciammaichella, and Ilaria Rossetti. CPC classifications span C07D 471/20 and multiple A61K therapeutic composition categories.

MALT-1 Modulators Patent Application, 13 Inventors, April 2026

The USPTO published patent application US20260109698A1 for MALT-1 modulators, covering compounds and compositions for treating diseases affected by MALT-1 modulation. The application names 13 inventors and was filed on December 18, 2025. This is a publication of a patent application — it does not yet constitute a granted patent or create enforceable intellectual property rights.

Cannabis Bioscience Nanoparticle Breast Cancer Treatment

Cannabis Bioscience International Holdings Inc has filed patent application US20260108536A1 for a cannabinoid-based nanoplatform composition targeting breast cancer treatment. The composition incorporates phytocannabinoids (THC, CBD, CBG, CBC) into nanoparticles smaller than 200 nm using nano-emulsification techniques for enhanced bioavailability and controlled release. The treatment targets ER+, PR+, HER2-positive, and triple-negative breast cancers at stages I and II by inhibiting VEGF pathways and inducing apoptosis.

Shingles Treatment Cannabinoid Nanoplatform CBD CBG

Cannabis Bioscience International Holdings Inc published USPTO patent application US20260108537A1 on April 23, 2026 (filed October 18, 2024, Application No. 18920359), disclosing a cannabinoid-based nanoplatform for treating shingles using CBD and CBG in oral capsule and topical cream formulations with particles smaller than 200 nm. The invention targets acute shingles symptoms and postherpetic neuralgia with systemic anti-inflammatory, antiviral, and neuroprotective effects alongside localized pain and itch relief. This is a patent publication event creating no compliance obligations.

Liposomal BCL Inhibitors for Hyperproliferative Disorders

USPTO published patent application US20260108534A1 on April 23, 2026, filed September 30, 2025 under Application No. 19345495. The application covers liposomes containing B-cell lymphoma (Bcl) protein inhibitors, pharmaceutical compositions thereof, and methods of using such formulations for treating hyperproliferative disorders. Inventors: Paul Tardi, Leon Wan, Shyam Madhusudan Garg, Jun Gao, and Philippe Legros.

Bradykinin Receptor Antagonist Compounds for Pain Relief

The USPTO published patent application US20260108535A1 on April 23, 2026, covering bradykinin receptor antagonist compounds for therapeutic use. The application (No. 19423236, filed December 17, 2025) specifies pharmaceutical compositions for treatment of urinary bladder pain and symptomatic relief of pain, burning, urgency, and frequency arising from lower urinary tract mucosa irritation caused by infection, trauma, surgery, endoscopic procedures, or catheter passage. The named inventors include Pathik Subhashchandra Brahmkshatriya, Vishal Bharatbhai Unadkat, Vishalgiri Gunvantgiri Goswami, Heta Nishil Pandya, and Sandip Pareshbhai Mehta.

Pharmaceutical Composition for Preventing Heart Disease and Pulmonary Hypertension in Animals

CARESIDE CO., LTD. has published patent application US20260108532A1, filed September 6, 2023, covering a pharmaceutical composition for preventing and treating heart disease and pulmonary hypertension in animals. The composition includes the active pharmaceutical ingredients pimobendan, enalapril, torsemide, and spironolactone. The application was published on April 23, 2026, under CPC classifications A61K and A61P relating to pharmaceutical preparations for cardiovascular conditions.

Cannabinoid Nanoplatform Treats Knee Osteoarthritis

USPTO published patent application US20260108539A1, filed October 21, 2024 by Cannabis Bioscience International Holdings Inc, covering a cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis via intra-articular injection. The composition combines phytocannabinoids CBG and CBC with hyaluronic acid, type II collagen, and calcium gluconate, targeting joint pain, stiffness, reduced mobility, inflammation, and cartilage degeneration in osteoarthritis patients. The nanoemulsification-based production process creates particles smaller than 200 nm with pre-sterilization via membrane filtration.